Article
p53 mutations in cyclophosphamide-associated bladder cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 May 1998
Khan M A, Travis L B, Lynch C F, Soini Y, Hruszkewycz A M, Delgado R M, Holowaty E J, van Leeuwen F E, Glimelius B, Stovall M, Boice J D, Tarone R E, Bennett W P
Abstract excerpt
Cyclophosphamide is a known bladder carcinogen, with cumulative dose directly related to increased risk. There is no consensus, however, on which major cyclophosphamide metabolite (i.e., acrolein or phosphoramide mustard) drives bladder carcinogenesis. We examined 19 cyclophosphamide-related bladder tumors to test the hypothesis that they might contain somatic mutations in the p53 tumor suppressor gene that could...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.